Expert Perspectives on the Latest TROPION-Lung01 Data
Edgardo Santos, MD, FACP, FCCP, provides expert insights into the latest data from the TROPION-Lung01 trial, emphasizing the potential implications of this information for treating patients with non-actionable biomarkers in NSCLC.
EP: 1.Beamion Lung 1: Zongertinib (BI 1810631) in Advanced HER2+ NSCLC
EP: 2.Expert Analysis on Recent Developments in DESTINY-Lung01 and DESTINY-Lung02 Trials
EP: 3.Expert Perspectives on the Latest TROPION-Lung01 Data
EP: 4.EMPOWER-Lung3: Cemiplimab Plus Chemotherapy in Advanced NSCLC
EP: 5.EMPOWER-Lung1 and 3 Squamous Subgroup Analysis: Expert Insights
EP: 6.Future Perspectives on the Treatment of NSCLC
This is a video synopsis/ summary of an OncLive Insights® featuring Edgardo S. Santos, MD, FACP, FCCP.
Santos highlighted data from the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan for patients with previously treated non–small cell lung cancer (NSCLC). Compared with docetaxel, datopotamab deruxtecan improved median progression-free survival to 4.4 from 3.7 months (HR, 0.75; P=.004). Subgroup analyses showed benefit across most patient subsets, though docetaxel remained superior for squamous histology. Despite the progression-free survival gain, an increased risk of interstitial lung disease occurred with datopotamab deruxtecan (7 grade 5 cases). Nonetheless, results of this early trial suggest datopotamab deruxtecan has activity in NSCLC post–platinum-based chemotherapy.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
